Physician profile
Reuben Dwayne Eliuk
NPI 1205987724
$878.96
in general payments reported to CMS, 2019-2025
13 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $46.00 · 2021: $92.23 · 2022: $41.67 · 2023: $190 · 2024: $160 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $230.14 | 2019-2025 | |
| Pfizer INC. | $186.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $169.43 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $68.44 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.16 | 2019-2025 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.24 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $32.67 | 2019-2025 | Wainua |
| Abbvie INC. | $27.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.89 | 2019 | |
| Amgen INC. | $18.72 | 2021 | |
| Ekos Corporation | $14.03 | 2019 | |
| Gilead Sciences, INC. | $13.87 | 2023 | |
| Melinta Therapeutics, LLC | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Eliuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.